In an attempt to diversify its early-stage pipeline, GSK has entered into a multi-programme agreement with ABL Bio to develop novel medicines for neurodegenerative diseases. The deal, which involves £77.1 M (US$99.45 M) in upfront and near-term payments as well as up to £2.075 B (US$2.68 B) in milestones, will leverage ABL’s blood-brain barrier shuttle platform, Grabody-B, to develop novel, therapeutic modalities for various neurodegenerative conditions. The agreement marks yet another neurology deal announced by GSK, following its recent partnerships with Vesalius Therapeutics and Muna Therapeutics focused on treatments for Parkinson’s disease and Alzheimer’s disease, respectively.